The Medical Letter - 2024
Search or Select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
May 27, 2024 (Issue 1703)  
  • Drugs for Hypertension   
    American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed...
May 13, 2024 (Issue 1702)  
April 29, 2024 (Issue 1701)  
April 15, 2024 (Issue 1700)  
April 1, 2024 (Issue 1699)  
  • Drugs for Bipolar Disorder   
    Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder...
  • Omalizumab (Xolair) for Food Allergy   
    Omalizumab (Xolair – Genentech), a recombinant anti-IgE monoclonal antibody FDA-approved for treatment of allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, has now also...
  • Addendum: Bupropion Safety in Pregnancy   
    Our December 11, 2023 article on Drugs for Depression included a single sentence on the safety of bupropion use during pregnancy: "The safety of bupropion during pregnancy has not been established; data from...
March 18, 2024 (Issue 1698)  
March 4, 2024 (Issue 1697)  
February 19, 2024 (Issue 1696)  
February 5, 2024 (Issue 1695)  
January 22, 2024 (Issue 1694)  
January 8, 2024 (Issue 1693)  
  • Treatment of Atrial Fibrillation   
    Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of...